Flávia Fonseca Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Flávia Fonseca Fernandes has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Juliana Carvalho Ferreira
Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sâo Paulo, Sâo Paulo, Brazil
3 shared publications - Cecilia Maria Patino
University of California, Los Angeles
2 shared publications - Albert Faro
Cystic Fibrosis Foundation, Bethesda, MD, USA
1 shared publication - Alexander Elbert
Cystic Fibrosis Foundation, Bethesda, MD, USA
1 shared publication - Alfredo Nicodemos Cruz Santana
Escola Superior de Ciências da Saúde, Brasília, Brazil
1 shared publication - Andreas Jung
Paediatric Pulmonology, University Children's Hospital Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 28 February 2026
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Respiratory Research & Clinical Practice
Evidence-based uncertainty: why equipoise is essential in clinical research
1. Methods in Epidemiologic, Clinical, and Operations Research-MECOR-program, American Thoracic Society/Asociación Latinoamericana del Tórax, Montevideo, Uruguay. 2. Departamento de Medicina, Universidade Federal de Catalão, Catalão (GO), Brasil. 3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (CA) USA. 4. Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP), Brasil.
- 28 February 2026
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Respiratory Research & Clinical Practice
Open AccessEvidence-based uncertainty: why equipoise is essential in clinical research
1. Methods in Epidemiologic, Clinical, and Operations Research-MECOR-program, American Thoracic Society/Asociación Latinoamericana del Tórax, Montevideo, Uruguay. 2. Departamento de Medicina, Universidade Federal de Catalão, Catalão (GO), Brasil. 3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (CA) USA. 4. Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP), Brasil.
- Open Access
- 20 December 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (6) , e20240295
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review
Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB). Methods: This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events. We searched the MEDLINE, EMBASE, Google Scholar, LILACS, and ClinicalTrials.gov databases, from their inception to January 31, 2024, with no limitation as to language or year of publication. The risk of bias was assessed by using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation approach. Results: A total of 3,668 studies were retrieved; only one (a randomized clinical trial) met the inclusion criteria and was included. In patients with MDR/RR-TB, treatment with the BPaLM regimen, when compared with the standard of care, reduced the risk of an unfavorable outcome (composite, number needed to treat [NNT] = 7); early treatment discontinuation (NNT = 8); adverse events and discontinuation (NNT = 12); and serious adverse events (NNT = 5). Conclusions: This systematic review of the use of BPaLM in patients with MDR/RR-TB, although it included only one study, showed that BPaLM is more effective than is the standard of care and has a better safety profile. That has major implications for guidelines on the treatment of MDR/RR-TB.
- 20 December 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (6) , e20240295
Open AccessBedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review
Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB). Methods: This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events. We searched the MEDLINE, EMBASE, Google Scholar, LILACS, and ClinicalTrials.gov databases, from their inception to January 31, 2024, with no limitation as to language or year of publication. The risk of bias was assessed by using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation approach. Results: A total of 3,668 studies were retrieved; only one (a randomized clinical trial) met the inclusion criteria and was included. In patients with MDR/RR-TB, treatment with the BPaLM regimen, when compared with the standard of care, reduced the risk of an unfavorable outcome (composite, number needed to treat [NNT] = 7); early treatment discontinuation (NNT = 8); adverse events and discontinuation (NNT = 12); and serious adverse events (NNT = 5). Conclusions: This systematic review of the use of BPaLM in patients with MDR/RR-TB, although it included only one study, showed that BPaLM is more effective than is the standard of care and has a better safety profile. That has major implications for guidelines on the treatment of MDR/RR-TB.
- Open Access
- 26 August 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 815-822
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
- 26 August 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 815-822
Open AccessImpact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
- 1 March 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (2) , 203-207
Year in review 2023 – Back to the future
- 1 March 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (2) , 203-207
Year in review 2023 – Back to the future
- Open Access
- 27 October 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (5) , e20230336
Twelve tips to manage a research project—advice for the young investigator
- 27 October 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (5) , e20230336
Open AccessTwelve tips to manage a research project—advice for the young investigator
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (1) , 83-87
The role of Clinical-Functional Vulnerability Index-20 to detect quality of life in older adults assisted in primary care
OBJECTIVE: To determine the cutoff point of the Clinical-Functional Vulnerability Index-20 to detect poor quality of life in the elderly in Primary Health Care. METHODS: This cross-sectional study was carried out in Primary Health Care units of Ceilandia (DF, Brasil) between September 2019 and January 2020. Four hundred and fifty-eight individuals were included in the study and answered the Clinical-Functional Vulnerability Index-20 (IVCF-20) and the World Health Organization Quality of Life - WHOQOL-BREF (validated to access quality of life) instruments. Based on the WHOQOL-BREF answers, three subgroups were created: poor, good and undetermined quality of life. The receiver operating characteristic curve (using Youden index) showed the IVCF-20 cutoff point to detect poor quality of life (in individuals with good quality of life as the Control Group), and therefore diagnostic tests were performed. RESULTS: The IVCF-20 cutoff point to detect poor quality of life was >= 11. The area under the receiver operating characteristic curve was 0.97 (95%CI 0.95-0.98). The IVCF-20 diagnostic tests showed good sensitivity (88.1%) and specificity (84.9%). CONCLUSIONS: The IVCF-20 >= 11 detected poor quality of life adequately in the elderly in Primary Health Care. These data suggest that elderly individuals with IVCF >= 11 should attend appointments more often in Primary Health Care or geriatrics collaborative care, considering the impact that quality of life can have on the elderly population's mortality.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (1) , 83-87
Open AccessThe role of Clinical-Functional Vulnerability Index-20 to detect quality of life in older adults assisted in primary care
OBJECTIVE: To determine the cutoff point of the Clinical-Functional Vulnerability Index-20 to detect poor quality of life in the elderly in Primary Health Care. METHODS: This cross-sectional study was carried out in Primary Health Care units of Ceilandia (DF, Brasil) between September 2019 and January 2020. Four hundred and fifty-eight individuals were included in the study and answered the Clinical-Functional Vulnerability Index-20 (IVCF-20) and the World Health Organization Quality of Life - WHOQOL-BREF (validated to access quality of life) instruments. Based on the WHOQOL-BREF answers, three subgroups were created: poor, good and undetermined quality of life. The receiver operating characteristic curve (using Youden index) showed the IVCF-20 cutoff point to detect poor quality of life (in individuals with good quality of life as the Control Group), and therefore diagnostic tests were performed. RESULTS: The IVCF-20 cutoff point to detect poor quality of life was >= 11. The area under the receiver operating characteristic curve was 0.97 (95%CI 0.95-0.98). The IVCF-20 diagnostic tests showed good sensitivity (88.1%) and specificity (84.9%). CONCLUSIONS: The IVCF-20 >= 11 detected poor quality of life adequately in the elderly in Primary Health Care. These data suggest that elderly individuals with IVCF >= 11 should attend appointments more often in Primary Health Care or geriatrics collaborative care, considering the impact that quality of life can have on the elderly population's mortality.